KPV vs Eloralintide
Side-by-side comparison of key properties, dosing, and research.
Immune SupportRecovery & Repair
KPVGLP-1 / Weight Loss Agonists
Eloralintide- Summary
- KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It powerfully suppresses intestinal and systemic inflammation via melanocortin receptors, making it valuable for IBD, gut healing, and wound repair.
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Half-Life
- Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades
- ~7 days (estimated, long-acting design)
- Admin Route
- Oral, SubQ, Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 500 mcg – 1 mg
- Under investigation in Phase 1/2 trials
- Frequency
- Once to twice daily
- Once weekly
- Key Benefits
- Reduces intestinal inflammation (IBD, Crohn's, colitis)
- Promotes gut mucosal healing and barrier integrity
- Accelerates wound healing topically
- Suppresses systemic inflammatory cytokines
- Antimicrobial properties against pathogens
- Reduces neuroinflammation when administered systemically
- May improve symptoms of inflammatory skin conditions
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Side Effects
- Generally very well tolerated
- Mild injection site reactions (SC)
- Rare: transient flushing
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Stacks With
- —
- —